



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 8, 2020

Murielle Lortie  
Chief Financial Officer  
Liminal BioSciences Inc.  
440 Armand-Frappier Boulevard, Suite 300  
Laval, Québec H7V 4B4

**Re: Liminal BioSciences Inc.**  
**Registration Statement on Form F-3**  
**Filed December 2, 2020**  
**File No. 333-251065**

Dear Ms. Lortie:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Abby Adams at (202) 551-6902 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Jaime L. Chase, Esq.